The hospital Ospedale Bambino Gesú, one of the most important pediatric centers in Italy, has decided to move forward with the acquisition of the system based on the successful experience obtained while enrolled in the HEOR study currently on-going to evaluate the clinical impact of rAST in patients with sepsis that includes several other relevant Institutions in the country.

“Our decision to move forward with the acquisition of ASTar has been based on the very positive experience we are having with the system in terms of ease of use, workflow and most importantly in terms of strong and consistent clinical results we are getting daily. The addition of ASTar will, certainly, help us provide better care to our critical patients”, said Dott.ssa Paola Bernaschi, Responsabile Unità Operativa Semplice Microbiologia dell’Ospedale Pediatrico Bambino Gesù – IRCSS.